Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
NewCo’s pipeline includes five investigational medicines
For patients with resectable early-stage gastric and gastroesophageal junction cancers
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Subscribe To Our Newsletter & Stay Updated